肝动脉、门静脉栓塞化疗联合射频消融治疗原发性肝癌的临床研究

Study on transcatheter hepatic artery chemoembolization combined with percutaneous portal vein chemoembolization and percutaneous radiofrequency ablation in treatment of unresectable hepatocarcinoma

目的探讨肝动脉栓塞化疗、门静脉栓塞化疗及射频消融治疗不能手术切除的原发性肝癌的临床价值。方法对2001年3月至2005年6月间58例不能手术切除的肝癌分别行肝动脉栓塞化疗(30例)或肝动脉栓塞化疗联合经皮门静脉栓塞化疗及射频消融(28例)。结果两组病人治疗后1年及2年生存率差异(P<0.05)、肿瘤缩小率差异(P<0.01)和ATP转阴率差异(P<0.05)均有统计学意义。结论对不能手术切除的肝癌,肝动脉栓塞化疗联合经皮门静脉栓塞化疗及射频消融能显著提高肿瘤缩小率、ATP转阴率及生存率。

Objective To explore the clinical value of transcatheter hepatic artery chemoembolization （TACE） combined with percutaneous portal vein chemoembolization （PVCE） and percutaneous radiofrequency ablation （PRFA） in treatment of unresectable hepatocarcinoma. Methods From Mar 2001 to Jun 2005,58 patients with unresectable hepatocarinoma were treated with TACE （30 cases） or TACE＋PVCE＋PRFA（28 cases）. Results After the treatment, the total survival rate in 1 year and 2 years was significant differece between two groups （p〈 0.05）. The tumor reduction rate had significant difference between two groups （p〈0.01）. For the patients of AlP positive, the AFP negative conversion rate was significant difference between two groups （p〈0.01）. Conclusion For unresectable hepatocarcinoma ,the use of TACE combined with PVCE and PRFA can significantly increase tumor reduction rate,survival rate and AFP negative conversion rate .